Malaysia
-
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Phase 2 · 225 people · 53 sites in 11 countries · Recruiting now
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer
Phase 3 · randomised · 477 people · 223 sites in 29 countries · Recruiting now